PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?
Success of enhanced communications in particular made one stakeholder wonder whether FDA could use it with non-breakthrough applications.
You may also be interested in...
Agency staff discuss how they offer early development advice to sponsors before a breakthrough decision is made and reassure them if the status is denied.
The CDER director said the US agency is always thinking about the next iteration of the prescription drug user fee program, but added that it has not yet discussed specifics.
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.